Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
The retrospective studies provide support for the use of predictive enrichment markers (PEMs) in clinical trials to assess the patient population likely to benefit from treatment with LUM-201.
- The retrospective studies provide support for the use of predictive enrichment markers (PEMs) in clinical trials to assess the patient population likely to benefit from treatment with LUM-201.
- The PEMs identified from the analysis of the Merck 020 study data are being used prospectively to select PGHD patients for enrollment in our ongoing OraGrowtH210 Trial.
- This manuscripts definition of patients with moderate GHD is aligned with the baseline IGF-1 and peak GH levels noted above.
- You should, therefore, not rely on these forward-looking statements as representingthe Companysviews as of any date subsequent to the date of this press release.